These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18157733)

  • 1. The burden of rheumatoid arthritis and access to treatment: a medical overview.
    Smolen J; Aletaha D
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S39-47. PubMed ID: 18157733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New therapeutic strategy of rheumatoid arthritis to reach the goal of suppression of joint destruction].
    Yamaguchi Y; Yamamoto K
    Clin Calcium; 2007 Apr; 17(4):463-73. PubMed ID: 17404474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The burden of rheumatoid arthritis and access to treatment: determinants of access.
    Lundqvist J; Kastäng F; Kobelt G; Jönsson B
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S87-93. PubMed ID: 18157560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug management of early rheumatoid arthritis - 2008.
    Sokka T; Mäkinen H
    Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):93-102. PubMed ID: 19233049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies to control disease in rheumatoid arthritis with tumor necrosis factor antagonists-an opportunity to improve outcomes.
    Keystone EC
    Nat Clin Pract Rheumatol; 2006 Nov; 2(11):594-601. PubMed ID: 17075598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics in rheumatoid arthritis.
    Ranganathan P
    Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The burden of rheumatoid arthritis and access to treatment: health burden and costs.
    Lundkvist J; Kastäng F; Kobelt G
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S49-60. PubMed ID: 18157732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current concepts in clinical therapeutics: disease-modifying drugs for rheumatoid arthritis.
    Pugh MC; Pugh CB
    Clin Pharm; 1987 Jun; 6(6):475-91. PubMed ID: 3319362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
    Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
    Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment and management of rheumatoid arthritis.
    Haraoui B
    J Rheumatol Suppl; 2009 Jun; 82():2-10. PubMed ID: 19509324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression in early rheumatoid arthritis.
    Combe B
    Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):59-69. PubMed ID: 19233046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
    Polinski JM; Mohr PE; Johnson L
    Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional disease-modifying antirheumatic drugs in early arthritis.
    Sokka T; Hannonen P; Möttönen T
    Rheum Dis Clin North Am; 2005 Nov; 31(4):729-44. PubMed ID: 16287594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Modern treatment of rheumatoid arthritis].
    Surányi P
    Orv Hetil; 2005 Oct; 146(40):2059-65. PubMed ID: 16259334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.
    Keystone E; Freundlich B; Schiff M; Li J; Hooper M
    J Rheumatol; 2009 Mar; 36(3):522-31. PubMed ID: 19228659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rituximab (MabThera)--a new biological medicine in rheumatoid arthritis therapy].
    Nemec P
    Vnitr Lek; 2007 Nov; 53(11):1199-210. PubMed ID: 18277630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of established rheumatoid arthritis with an emphasis on pharmacotherapy.
    Blom M; van Riel PL
    Best Pract Res Clin Rheumatol; 2007 Feb; 21(1):43-57. PubMed ID: 17350543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are glucocorticoids DMARDs?
    Bijlsma JW; Hoes JN; Van Everdingen AA; Verstappen SM; Jacobs JW
    Ann N Y Acad Sci; 2006 Jun; 1069():268-74. PubMed ID: 16855154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early rheumatoid arthritis.
    Machold KP; Nell V; Stamm T; Aletaha D; Smolen JS
    Curr Opin Rheumatol; 2006 May; 18(3):282-8. PubMed ID: 16582693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls.
    Laurberg TB; Frystyk J; Ellingsen T; Hansen IT; Jørgensen A; Tarp U; Hetland ML; Hørslev-Petersen K; Hornung N; Poulsen JH; Flyvbjerg A; Stengaard-Pedersen K
    J Rheumatol; 2009 Sep; 36(9):1885-91. PubMed ID: 19684150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.